Cell Therapeutics (CTIC)
Cell Therapeutics Beneish M-Score
View CTIC Beneish M-Score with YCharts Pro.
Access these YCharts Pro features:
Export any data you want
Save any chart as an image
Utilize advanced screener power
View 30 years of financial history
over 90 advanced calculations
Enjoy an advertising free experience
CTIC Beneish M-Score Range, Past 5 Years
| Minimum | 68.67 | Dec 2008 |
| Maximum | 68.67 | Dec 2008 |
| Average | 68.67 |
About Beneish M Score
The Beneish M Score helps to uncover companies who are likely to be manipulating their reported earnings. Companies with a higher score are more likely to be manipulators. This is a probabilistic model, so it will not detect manipulators with 100% accuracy.
The best cut-off point depends on the costs mistakenly classifying in one of two ways:
1) Classifying firm that is manipulating earnings as a non-manipulator (Type I error), and
2) Classifying a firm as a manipulator when it actually was not manipulating (Type II Error).
Here are optimal cut-offs according to Beneish, presented as the score followed by the cost of Type I error relative to cost of Type II error):
M Score HTML Table:
| Score | Relative Error Costs (Type I:Type II) |
|---|---|
| M Score > -1.49 | (10:1) | M Score > -1.78 | (20:1) | M Score > -1.89 | (40+:1) |
Beneish excluded financial institutions from his sample when calculating the M-Score, so extreme care should be taken when looking at M-Scores of financial firms - their business models are different from the manufacturing and other service firms that Beneish used in his study.
If you want more details, here is the original Beneish M Score Paper, or you can learn about our calculation by clicking "Learn More" below.
Learn More
You may also be interested in these CTIC related companies
CTIC News
CellTherapeutics (CTIC) Gets Conditional EC Marketing Authorization for Pixuvri
May 11, 9:14AM Street Insider
May 11, 9:14AM Street Insider
Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones
Apr 20, 1:30AM PR Newswire
Apr 20, 1:30AM PR Newswire
Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
Apr 19, 8:00PM PR Newswire
Apr 19, 8:00PM PR Newswire
Cell Therapeutics (CTIC) to Acquire Rights on S*BIO's Pacritinib JAK2 Inhibitor
Apr 19, 6:54AM Street Insider
Apr 19, 6:54AM Street Insider
Cell Therapeutics, Inc. (CTI) to Host Conference Call April 19, 8:30 AM ET
Apr 18, 8:00PM PR Newswire
Apr 18, 8:00PM PR Newswire
Cell Therapeutics and Keryx Biopharmaceuticals Hope for Help From the TREAT Act
Mar 22, 8:20AM Marketwire
Mar 22, 8:20AM Marketwire
Cell Therapeutics and Avanir Pharmaceuticals Look to Make Headway in Strengthening Biotech Industry
Mar 12, 8:20AM Marketwire
Mar 12, 8:20AM Marketwire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CTIC | 0.91 | -0.01 | -1.09% | 206.22M |
| CTHR | 3.89 | +0.03 | +0.78% | 75.66M |
| CTGX | 12.45 | +0.16 | +1.30% | 230.70M |
| CTFO | 4.55 | -0.09 | -1.94% | 114.98M |
| CTEL | 10.58 | -0.19 | -1.76% | 408.92M |
| CTCT | 20.58 | +0.12 | +0.59% | 622.13M |
| CTCM | 9.35 | -0.10 | -1.06% | 1.471B |
| CTB | 15.21 | -0.25 | -1.62% | 947.58M |
| CTAS | 37.31 | -0.41 | -1.09% | 4.840B |
| CSU | 9.67 | +0.12 | +1.26% | 272.11M |
